The Dallas Cowboys ruled out right guard Zack Martin and cornerback Trevon Diggs with injuries on Saturday, one day prior to a road game against the Washington Commanders. Martin has been dealing with ankle and shoulder injuries and didn't practice at all this week before initially being listed as doubtful to play on Friday. He also physically struggled during Monday night's loss to the Houston Texans. Martin, who turned 34 on Wednesday, has started all 162 games played in 11 seasons with the Cowboys. He's a nine-time Pro Bowl selection and a seven-time first-team All-Pro. Diggs has been dealing with groin and knee injuries. He was listed as questionable on Friday before being downgraded Saturday. Diggs, 26, has 37 tackles and two interceptions in 10 games this season. The two-time Pro Bowl pick led the NFL with 11 picks in 2021 and has 20 in 57 games. The Cowboys elected not to activate receiver Brandin Cooks (knee) for the game. He returned to practice earlier this week and he was listed as questionable on Friday. Dallas activated offensive tackle Chuma Edoga (toe) and defensive end Marshawn Kneeland (knee) off injured reserve Saturday, placed safety Markquese Bell (shoulder) on IR and released defensive end KJ Henry. Tight end Jake Ferguson (concussion) was previously ruled out. Tight end Princeton Fant was elevated from the practice squad to replace him. Cornerback Kemon Hall also was elevated from the practice squad. --Field Level Media
Enfusion stock hits 52-week high at $10.4 amid growth optimismAI in 2025: Transforming the B2B Sales Landscape
Attention Long-Time SoFi Technologies Shareholders: Thursday's Unusual Options Activity Could Guide Your Next Investment MoveDirector Christopher Nolan's next work will be a modern film adaptation of Homer's "The Odyssey," bringing the Greek classic to IMAX screens in 2026. "Christopher Nolan’s next film ‘The Odyssey’ is a mythic action epic shot across the world using brand new IMAX film technology," Universal Pictures announced on X. "The film brings Homer’s foundational saga to IMAX film screens for the first time and opens in theaters everywhere on July 17, 2026." Homer's epic poem "The Odyssey" tells the story of the Greek hero Odysseus, the King of Ithaca, as he embarks on a ten-year journey from Troy back to Ithica following the Trojan War. Along the way, Odysseus and crew encounter several challenges including a Cyclops and the Sirens. The film reportedly star Tom Holland, Zendaya, Matt Damon, Robert Pattinson, Anne Hathaway, Lupita Nyong’o and Charlize Theron, according to Deadline . "The Odyssey" will be Nolan's second film with Universal Pictures, with "Oppenheimer" having been released in partnership with the distributor in 2023. The film went on to win seven Academy Awards, including Best Picture, Best Director for Nolan and Best Actor for Cillian Murphy. Nolan has also directed other major hits including "The Dark Knight" franchise, "Interstellar," "Dunkirk" and "Inception." (Universal Pictures and this NBC station are both part of the NBCUniversal family.)A man has been detained by authorities in connection to the murder of UnitedHealthcare CEO Brian Thompson outside a Manhattan hotel on Wednesday. On Monday, investigators took a man into custody in central Pennsylvania after finding a gun and a silencer, as well as false ID cards similar to those used by the killer. Investigators were tipped off about the man who was spotted reading at a McDonald’s in Altoona by an employee who thought he looked like the suspected killer, according to CNN. The alleged suspect has been named as Luigi Mangione, 26. He has not been charged for murder. A three-page handwritten manifesto listing his personal grievances against the healthcare industry, including the profits made and the pursuit of alleged crooked motives, was found. In a press conference on Monday (local time) New York City Mayor Eric Adams, alongside chief of detectives Joseph Kenny and New York City police commissioner Jessica Tisch, said authorities had detained a “strong person of interest”. “He matches the description of the identification we’ve been looking for,” Mayor Adams said. “He’s also in possession of several items that we believe will connect him to this incident. “How did we do it? Good old-fashioned police work.” Tisch said Mangione was found with a mask consistent with those of the shooter, while the fraudulent IDs were used to check into a hostel before the shooting incident. The handwritten document spoke to both his “motivation and mindset”, with Tisch adding New York detectives were travelling to Pennsylvania to interview Mangione. “This case, which captured the attention of an entire nation, is another example of how connected we are and how important it is to work together, share information, and pursue every lead,” Tisch said. “We must also acknowledge the instrumental role the media and the public played in this case. The images we shared with the public were spread far and wide, and the tips we received led to the recovery of crucial evidence. “We should never underestimate the power of the public to be our eyes and our ears in these investigations.” Kenny said police were “not done here”, as law enforcement were continuing to scrub his social media profiles, online fingerprint, while also carrying out ballistic tests of the "ghost gun" found in Mangione's possession. "The gun appears to be a ghost gun, it may have been made on a 3D printer , the capability of firing a 9mm round, obviously that will come out in our ballistic testing," the chief of detectives said. Kenny said Mangione was not known to police prior to the shooting. The Post reported Mangione had subscribed to anti-capitalist and climate change causes, as well as demonstrating his hatred for the healthcare industry online, according to police sources. In the Goodreads website, which allows people to exchange book recommendations, Mangione liked a range of quotes from Aldous Huxley to Socrates. He also liked quotes from Theodore Kaczynski, known as the “Unabomber”, who was a domestic terrorist for almost two decades having planted bombs against people advancing modern technology which posed a threat to the natural environment. “Imagine a society that subjects people to conditions that make them terribly unhappy then gives them the drugs to take away their unhappiness,’’ one Kaczynski quote liked by Mangione read. The quote continues: “Instead of removing the conditions that make people depressed modern society gives them antidepressant drugs. In effect antidepressants are a means of modifying an individual's internal state in such a way as to enable him to tolerate social conditions that he would otherwise find intolerable.”
The biggest threat to markets and the economy in 2025Luigi Mangione, who was arrested and charged with murder in the shooting death of United Healthcare CEO Brian Thompson, once belonged to a group of Ivy League gamers who played assassins, a member of the group told NBC News. In the game, called "Among Us," some players are secretly assigned to be killers in space who perform other tasks while trying to avoid suspicion from other players. > Watch NBC Bay Area News 📺 Streaming free 24/7 Alejandro Romero, who attended the University of Pennsylvania with Mangione and was a member of the same Discord group, said he was shocked when news broke on social media that Mangione had been taken into police custody. "I just found it extremely ironic that, you know, we were in this game and there could actually be a true killer among us," he said. "As soon as his photo and name popped up on X, my friend texted me asking if I knew him, and then either I was calling some 10 friends or they were calling me," Romero added. "I didn't speak to anybody today who wasn't already aware of what had happened." Mangione, 26, was arrested Monday morning in a McDonald's restaurant in Altoona, Pennsylvania, after an employee spotted him. Police found a firearm, believed to have been 3D-printed, and a handwritten document on Mangione "that speaks to both his motivation and mindset," New York Police Commissioner Jessica Tisch said at a news conference. He was also carrying fake identification and a passport, authorities said. In New York, Mangione was charged with murder, possession of a loaded firearm, possession of a forged instrument and criminal possession of a weapon, according to court documents. Authorities in Pennsylvania charged Mangione with carrying firearms without a license, forgery, tampering with records or identification, possessing instruments of crime and providing false identification to police. In a statement on X on Monday night, a member of the Mangione family said they are "shocked and devastated by Luigi's arrest." "We offer our prayers to the family of Brian Thompson and we ask people to pray for all involved," wrote Nino Mangione, a Republican member of the Maryland House of Delegates. Romero, who said he has not spoken to or seen Mangione since 2020, described him as a typical college student who did not stand out to him. "He just fit a mold," Romero said. "He just seemed like any other normal frat dude that you could see at a frat party." His final year in college was cut short when the pandemic hit. Students were forced off campus in their last semester and did not return for commencement. The Discord group was one way to stay connected, Romero said, but members began to go their separate ways as they got full-time jobs or embarked on long trips. During some of those years, Mangione left behind a digital footprint that included reviewing “Industrial Society and Its Future,” also known as the “Unabomber Manifesto” by Ted Kaczynski, on Goodreads, a platform for book reviews and recommendations. It served as the ideological reasoning for Kaczynski’s yearslong mail bomb campaign that killed three people and injured 23 others. Mangione became significantly more active on X in 2021 after five years not posting or reposting content, according to a review of his account. Asked about the change in Mangione's online persona, Romero said that question is circulating among his friend group. "I feel like people are unsure how to label him," he said. "I'm personally struggling to understand how this all fits." This story first appeared on NBCNews.com. More from NBC News:
Prepare for uncertain, shock-prone future, Bank of Canada head tells B.C. crowdIndiana quarterback Rourke earns Jon Cornish Trophy as top Canadian in NCAA football
La Unidad de Hackers Éticos de Thales crea un metamodelo para detectar imágenes falsas generadas por IA
Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update. Second Fiscal Quarter 2025 Highlights: In the run up to the close of 2024 and the second quarter of fiscal year 2025 ("Q2 FY2025”), HeartSciences saw across the board material progress and more positive developments for the field of AI-ECG, its MyoVista® wav ECG TM device, MyoVista® Insights TM cloud-native platform and first cloud-based AI-ECG algorithms. A summary of current status and business highlights during Q2 FY2025 include: "We end calendar 2024 in a strong position, having made significant progress. HeartSciences is the only Company developing across the board ECG solutions to upgrade archaic devices, clinical capabilities, and reporting and management systems which are a necessity for any healthcare system worldwide.” "By calendar year end, our Phase 1 MyoVista Insights cloud-native platform will be complete after millions of dollars of investment. Feedback to date has been excellent and we are in discussions for early deployment in test environments. Our ultimate vision is to offer a path to modernize legacy ECG management systems, as they are generally inflexible and costly due to decades-old IT architecture. Instead, we will provide a next-gen, cybersecure cloud-native system to meet the sophisticated data driven needs of today's health systems. Our AI-ECG marketplace will facilitate far quicker rollout of AI-ECG and allow patients and health systems environments to realize their significant benefits.” "Our MyoVista wav ECG is approaching FDA submission and will allow next-to-patient, immediate access to AI-ECG results which is suitable for many frontline healthcare settings and territories around the world. Our versatility will enable us to deliver AI-ECG solutions across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services.” concluded Mr. Simpson. Second Quarter Fiscal 2025 Financial Results There were no revenues during Q2 FY2025. As of October 31, 2024, cash and cash equivalents were approximately $4.1 million and shareholders' equity was approximately $4.0 million. Complete financial results have been filed in the Company's Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission and is available on the Company's website. About HeartSciences HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECGTM, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. For more information, please visit: https://www.heartsciences.com . X: @HeartSciences Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 29, 2024, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2024, filed with the SEC on September 12, 2024, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024, filed with the SEC on December 16, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov . Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. Contacts: HeartSciences Gene Gephart +1-682-244-2578 Ext. 2024 [email protected] Investors Gilmartin Group Vivian Cervantes [email protected]Figure 1 Site Rendering of NOVONIX's New Facility BRISBANE, Australia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited NVX NVX ) ("NOVONIX" or "the Company"), a leading battery materials and technology company, announced today a conditional commitment to NOVONIX through one if its wholly-owned U.S.-based subsidiaries ("Borrower"), from the U.S. Department of Energy ("DOE") through the Loan Programs Office ("LPO") for a direct loan of up to US$754.8 million ($692 million in principal and $62.8 million in capitalized interest) to be applied towards partially financing a proposed new facility in Chattanooga, Tennessee (the "New Facility"). The proposed financing is being offered under the DOE LPO's Advanced Technology Vehicles Manufacturing ("ATVM") Loan Program. If finalized, the loan would be applied towards partially financing the construction of the New Facility in Chattanooga, Tennessee, to manufacture synthetic graphite primarily for use in electric vehicle ("EV") batteries. At full capacity, the new facility is expected to produce approximately 31,500 tonnes per annum ("tpa") of synthetic graphite, which can support the production of lithium-ion batteries for approximately 325,000 EVs each year. China currently has over 95% market share for battery grade graphite 1 . The new facility is expected to reach full production capacity by the end of 2028 and is anticipated to create 450 full-time operational jobs and 500 construction jobs. Dr. Chris Burns, CEO of NOVONIX said, "This announcement is the culmination of years of hard work and is another critical milestone for our anode materials business towards our target production of 150,000 tpa in North America. This conditional commitment from the government to invest in our new facility continues to underscore the focus on localizing critical materials in the battery supply chain, such as graphite. Recent announcements from China to further scrutinize the export of battery-grade graphite to the United States highlight the importance of domestic production of high-performance, battery-grade synthetic graphite. Our offtake agreements with strong partners have strengthened our leadership in onshoring the synthetic graphite supply chain in North America and supporting the path towards U.S. energy independence." This year, NOVONIX has signed binding offtake agreements to supply synthetic graphite to Panasonic Energy 2 , Stellantis 3 , and PowerCo 4 . To meet this demand, the Company has previously discussed plans to build a new facility in the southeastern United States which could expand up to 75,000 tpa or production capacity. This proposed ATVM Program loan would support the construction of the first phase of the New Facility and the initial production capacity of 31,500 tpa. NOVONIX plans to subsequently expand the production capacity of this site to its target of 75,000 tpa of synthetic graphite production, any such expansion being dependent on customer demand and access to additional financing. NOVONIX's Riverside facility, also located in Chattanooga, is poised to become the first large-scale production site dedicated to high-performance synthetic graphite for the battery sector in North America. It is slated to begin commercial production in 2025, with plans to grow output to 20,000 tpa to meet current customer commitments. Previously, the Company announced that the DOE's Office of Manufacturing and Energy Supply Chains ("MESC") awarded the Company a US$100 million grant 5 and that it was selected for a US$103 million investment tax credit 6 towards the funding of the Riverside facility. Key terms of the DOE's conditional commitment, including those set forth in a non-binding term sheet attached to the conditional commitment letter signed by the DOE, NOVONIX and the Borrower, include: The loan is for a maximum amount of US$754.8 million, which includes up to US$692.0 million in principal and up to US$62.8 million in capitalized interest and will be structured in two tranches based on a phased completion of infrastructure and production lines from a total eligible investment of US$943.6 million. The loan will be comprised of two primary tranches that will have terms of 15 years and 10 years, respectively, from the date of first payment of each. The first tranche will be to support the site and infrastructure for the New Facility and 21,000 tpa of production capacity, while the second tranche will support an additional 10,500 tpa of production capacity. An additional tranche to fund eligible project costs will be subject to repayment upon receipt of any proceeds derived from the monetization of any tax credit received by the Company or the Borrower related to the New Facility under the Qualifying Advanced Energy Project Allocation Program. The loan will be guaranteed by the Company and secured by a first priority security interest in all assets of the Borrower, equity interests in and, with certain exceptions, assets of certain of NOVONIX's existing subsidiaries. Each advance of loan proceeds will have a separate interest rate set by the Federal Financing Bank under the general supervision of the Secretary of Treasury at the time that the respective advance is made. While this conditional commitment demonstrates DOE's intent to finance the New Facility, DOE must complete an environmental review, and the Company must satisfy certain technical, commercial, legal, environmental, and financial conditions before DOE can decide whether to enter into definitive financing documents and fund the loan. A binding loan agreement from DOE is also subject to the satisfactory completion of due diligence by DOE, satisfaction of conditions precedent specified in the term sheet, approval of the NOVONIX Board, receipt of required governmental and third-party consents, and the negotiation and execution of binding loan documents. Once binding loan documents have been signed, NOVONIX and the Borrower will need to satisfy certain conditions precedent prior to loan closing, and / or prior to first and subsequent advances of loan proceeds. This announcement has been authorised for release by Admiral Robert J Natter, USN Ret., Chairman. About NOVONIX NOVONIX is a leading battery technology company revolutionizing the global lithium-ion battery industry with innovative, sustainable technologies, high-performance materials, and more efficient production methods. The Company manufactures industry-leading battery cell testing equipment, is growing its high-performance synthetic graphite material manufacturing operations, and has developed a patented all-dry, zero-waste cathode synthesis process. Through advanced R&D capabilities, proprietary technology, and strategic partnerships, NOVONIX has gained a prominent position in the electric vehicle and energy storage systems battery industry and is powering a cleaner energy future. To learn more, visit us at www.novonixgroup.com or on LinkedIn and X . For NOVONIX Limited Scott Espenshade, ir@novonixgroup.com (investors) Stephanie Reid, media@novonixgroup.com (media) Cautionary Note Regarding Forward-Looking Statements This communication contains forward-looking statements about the Company and the industry in which we operate. Forward-looking statements can generally be identified by use of words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or other similar expressions. Examples of forward-looking statements in this communication include, among others, statements we make regarding our target production capacity and commencement of commercial production at our Riverside facility, our plans to build a new production facility and achieve initial and total production capacities, and our efforts to finance this new production facility with a loan from the LPO. We have based such statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Such forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the timely deployment and scaling of our furnace technology, our ability to meet the technical specifications and demand of our existing and future customers, the accuracy of our estimates regarding market size, expenses, future revenue, capital requirements, needs and access for additional financing, the availability and impact and our compliance with the applicable terms of government support, including the DOE MESC grant and, if a definitive agreement is executed and the loan is funded, the LPO loan, our ability to satisfy the conditions precedent to our entering into definitive loan documents and to the DOE's funding the LPO loan and, if the loan is obtained, our ability to comply with the restrictions and obligations under the loan documents, our ability to obtain patent rights effective to protect our technologies and processes and successfully defend any challenges to such rights and prevent others from commercializing such technologies and processes, and regulatory developments in the United States, Australia and other jurisdictions. These and other factors that could affect our business and results are included in our filings with the U.S. Securities and Exchange Commission ("SEC"), including the Company's most recent annual report on Form 20-F. Copies of these filings may be obtained by visiting our Investor Relations website at www.novonixgroup.com or the SEC's website at www.sec.gov . Forward-looking statements are not guarantees of future performance or outcomes, and actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Accordingly, you should not place undue reliance on forward-looking statements. Any forward-looking statement in this communication is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. 1 Benchmark Minerals Intelligence Anode Price Assessment September 2024 2 Panasonic Energy and NOVONIX Sign Binding Off-Take Agreement - NOVONIX 3 NOVONIX and Stellantis Sign Binding Offtake Agreement - NOVONIX 4 NOVONIX and PowerCo SE Sign Binding Offtake Agreement - NOVONIX 5 NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy - NOVONIX 6 U.S. Government Selects NOVONIX to Receive US$103 Million in Qualifying Advanced Energy Project Tax Credits - NOVONIX A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a660b84-f19e-4636-b981-d532b2029ace © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.